Person:
García Carbonero, Rocío

Loading...
Profile Picture
First Name
Rocío
Last Name
García Carbonero
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Medicina
Department
Medicina
Area
Medicina
Identifiers
UCM identifierScopus Author IDDialnet ID

Search Results

Now showing 1 - 3 of 3
  • Publication
    Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance
    (MDPI, 2021-05-27) Soldevilla, Beatriz; López López, Angeles; Lens Pardo, Alberto; Carretero Puche, Carlos; Lopez Gonzalvez, Angeles; La Salvia, Anna; Gil Calderon, Beatriz; Riesco Martinez, Maria C.; Espinosa Olarte, Paula; Sarmentero, Jacinto; Rubio-Cuesta, Beatriz; Rincón, Raúl; Barbas, Coral; García Carbonero, Rocío
    Purpose: High-throughput “-omic” technologies have enabled the detailed analysis of metabolic networks in several cancers, but NETs have not been explored to date. We aim to assess the metabolomic profile of NET patients to understand metabolic deregulation in these tumors and identify novel biomarkers with clinical potential. Methods: Plasma samples from 77 NETs and 68 controls were profiled by GC−MS, CE−MS and LC−MS untargeted metabolomics. OPLS-DA was performed to evaluate metabolomic differences. Related pathways were explored using Metaboanalyst 4.0. Finally, ROC and OPLS-DA analyses were performed to select metabolites with biomarker potential. Results: We identified 155 differential compounds between NETs and controls. We have detected an increase of bile acids, sugars, oxidized lipids and oxidized products from arachidonic acid and a decrease of carnitine levels in NETs. MPA/MSEA identified 32 enriched metabolic pathways in NETs related with the TCA cycle and amino acid metabolism. Finally, OPLS-DA and ROC analysis revealed 48 metabolites with diagnostic potential. Conclusions: This study provides, for the first time, a comprehensive metabolic profile of NET patients and identifies a distinctive metabolic signature in plasma of potential clinical use. A reduced set of metabolites of high diagnostic accuracy has been identified. Additionally, new enriched metabolic pathways annotated may open innovative avenues of clinical research.
  • Publication
    Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?
    (MDPI, 2021-04-03) La Salvia, Anna; Espinosa Olarte, Paula; Riesco Martínez, María del Carmen; Anton Pascual, Beatriz; García Carbonero, Rocío
    Neuroendocrine tumors (NETs) are a heterogeneous family of neoplasms of increasing incidence and high prevalence due to their relatively indolent nature. Their wide anatomic distribution and their characteristic ability to secrete hormonally active substances pose unique challenges for clinical management. They are also characterized by the common expression of somatostatin receptors, a target that has been extremely useful for diagnosis and treatment (i.e., somatostatin analogues (SSAs) and peptide-receptor radionuclide therapy (PRRT)). Chemotherapy is of limited use for NETs of non-pancreatic origin, and the only approved targeted agents for advanced progressive NETs are sunitinib for those of pancreatic origin, and everolimus for lung, gastrointestinal and pancreatic primaries. Despite recent therapeutic achievements, thus, systemic treatment options remain limited. In this review we will discuss the state-of-the-art targeted therapies in the field of NETs, and also future perspectives of novel therapeutic drugs or strategies in clinical development, including recently presented results from randomized trials of yet unapproved antiangiogenic agents (i.e., pazopanib, surufatinib and axitinib), PRRT including both approved radiopharmaceuticals (177Lu-Oxodotreotide) and others in development (177Lu-Edotreotide, 177Lu-Satoreotide Tetraxetan), immunotherapy and other innovative targeted strategies (antibody-drug conjugates, bites,…) that shall soon improve the landscape of personalized treatment options in NET patients.
  • Publication
    Cáncer de mama de alto riesgo : impacto de la selección de pacientes en la supervivencia
    (Universidad Complutense de Madrid, Servicio de Publicaciones, 2003) García Carbonero, Rocío; Enríquez de Salamanca, Fernando; Paz-Ares, Luis; Cortés-Funes, Hernán
    El tratamiento con quimioterapia adyuvante en pacientes con carcinoma de mama resecable aumenta significativamente la supervivencia. No obstante, el pronóstico de ciertos subgrupos de pacientes, particularmente las mujeres con afectación de más de 10 adenopatías axilares, continúa siendo desalentador a pesar del tratamiento complementario. A lo largo de la última década se han desarrollado estrategias terapéuticas más agresivas en este subgrupo de pacientes de alto riesgo con el objetivo de mejorar su supervivencia. Los resultados obtenidos en distintos estudiados de fase II con esquemas de quimioterapia a altas dosis (QAD) y soporte con células progenitoras hematopoyéticas, realizados en una sola institución y sin brazo control, son espermatozoides. Los criterios de selección empleados para la inclusión de pacientes en estos estudios generalmente incluyen mujeres menores de 60 años, sin enfermedades concomitantes severas y sin progresión en el seno del tratamiento con quimioterapia convencional. Adicionalmente, estas pacientes son sometidas a estudios de extensión exhaustivos para descartar la presencia de enfermedad micrometastásica. El proceso de selección de pacientes previo a su inclusión en estudios con QAD ha demostrado tener un claro impacto en la supervivencia en dos estudios llevados a cabo en otro tipo de tumores. El objetivo de este estudio es analizar el impacto de los criterios de selección empleados en los estudios con QAD y soporte con células progenitoras hematopoyéticas, en la supervivencia de pacientes con cáncer de mama de alto riesgo tratadas con quimioterapia convencional. Los resultados globales de esta tesis demuestran que los criterios de selección de pacientes empleados en los ensayos fase II no controlados con QAD en mujeres con cáncer de mama de alto riesgo son un factor pronóstico independiente en la supervivencia. Este hecho explica, al menos parcialmente, los mejores resultados obtenidos con esta nueva estrategia terapéutica cuando se comparan con los obtenidos con quimioterapia convencional en las series históricas.